Vasoconstrictor effects of midodrine, ST 1059, noradrenaline, etilefrine and norfenefrine on isolated dog femoral arteries and veins.
D015078:2-Hydroxyphenethylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D004285:Dogs; D005039:Etilefrine / Q000494:pharmacology; D005263:Femoral Artery / Q000187:drug effects; D005268:Femoral Vein / Q000187:drug effects; D066298:In Vitro Techniques; D008879:Midodrine / Q000031:analogs & derivatives / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D009655:Octopamine / Q000031:analogs & derivatives*; D014662:Vasoconstrictor Agents
D000316:Adrenergic alpha-Agonists; D014662:Vasoconstrictor Agents; D009655:Octopamine; C006146:ST 1059; D008879:Midodrine; D015078:2-Hydroxyphenethylamine; C005310:norfenefrine; D009638:Norepinephrine; D005039:Etilefrine